<![CDATA[DEC-C Plus Venetoclax May Quickly Replace IV HMA Regimens in AML]]>

Summary

Physicians discussed the potential for oral DEC-C plus venetoclax combination to rapidly replace intravenous HMA regimens in acute myeloid leukemia treatment. This represents a discussion of therapeutic positioning rather than new clinical data or regulatory action.